<abstract xmlns="http://www.w3.org/1999/xhtml">

Adipose tissue secretes dozens of biologically active molecules known as adipokines or adipocytokines. Apelin receptor early endogenous ligand (ELABELA, also known as ELA or APELA) is a circulating signaling protein expressed in placental tissue that binds to apelin receptors. The first animal experimental findings suggested that the ELABELA deficiency might be responsible for the pathogenesis of preeclampsia--like symptoms, i.e., hypertension and proteinuria in mice. Exogenous ELABELA supplementation reverted preeclampsia symptoms and normalized fetal birth weight in mice. Several in vitro studies confirmed that ELABELA supplementation could improve trophoblast cell functions such as invasiveness and proliferation capacity. Thus, the ELABELA axis could serve as the target of innovative therapies for gestational complications. Nonetheless, most human studies do not support the thesis that disturbances in ELABELA secretion in early pregnancy are associated with an increased risk of preeclampsia. Therefore, it is unlikely that ELABELA could serve as a novel early marker of preeclampsia in humans. Alterations in the ELABELA secretion have also been discovered among patients with other gestational complications such as GDM and fetal growth restriction.
</abstract>

ELABELA as a Marker of Gestational Complications – A Review

<abstract xmlns="http://www.w3.org/1999/xhtml">

The genes considered in this study, namely, <italic>LYN, CCL2, ITGB3</italic> and <italic>IL6</italic> can be related to immune response in porcine buccal mucosa cells primary cultured <italic>in vitro</italic>. These genes are also responsible for, inter alia, cell migration, differentiation, proliferation and apoptosis, intracellular signal transduction, extracellular matrix binding and wound healing. A total of 20 pubertal crossbred Landrace gilts bred on commercial farms were used to obtain buccal mucosa cell cultures, which were harvested on the 7th, 15th and 30th day after initiation of the culture. Expression levels of <italic>LYN, CCL2, ITGB3</italic> and <italic>IL6</italic> were evaluated employing Real-Time Quantitative Polymerase Chain Reaction. All studied genes showed expression. The expression of <italic>CCL2</italic> on day 15 was the highest of all factors measured. The greatest difference between the measurements occurred in gene <italic>IL6,</italic> between 7th and 15th day, while the least difference between the measurements occurred in gene <italic>LYN</italic>, between 7th and 15th day. Moreover, on the 7th day, <italic>LYN</italic> presented the lowest expression among all studied genes. Although <italic>in vitro</italic> conditions are much more controlled than <italic>in vivo</italic> conditions, all the factors that may positively or negatively affect cultured cells still cannot be fully predicted. Nevertheless, <italic>LYN, CCL2, ITGB3</italic> and <italic>IL6</italic> are a valuable starting point for studying further immunological processes in oral mucosal epithelial cells. Given their high regenerative potential, research into them is a highly valuable source of information for future wound healing therapies, where immunological processes should be carefully considered.
</abstract>

Potential Role of LYN, CCL2, ITGB3 and IL6 Genes in the Immune Response of Porcine Buccal Mucosa Cells

<abstract xmlns="http://www.w3.org/1999/xhtml">

The iridocorneal endothelial syndrome manifests in three clinical types: Chandler syndrome, progressive iris atrophy, and Cogan-Reese syndrome. It is caused by the presence of abnormal corneal endothelium on the iris stroma and anterior chamber angle leading to usually unilateral, progressive iris atrophy, glaucoma, and/or corneal edema. The etiology is yet unclear. It affects mostly young adults, mostly females. Management of iridocorneal endothelial syndrome is complex: conservative and surgical, depending on the stage of the disease and intensity of present symptoms. A 30-year-old female with a medical history of the iridocorneal endothelial syndrome was reported to the Ophthalmology Department for consultation. Slit-lamp examination revealed iris atrophy and superior-nasal corectopia in the left eye. On gonioscopy, the angle was wide open in the right eye, but there were iridocorneal adhesions and incomplete angle-closure in the left eye. The patient was provided with maximum local therapy consisting of three anti-glaucoma medications. On later check-ups, the patient presented corneal edema and increased intraocular pressure. She was qualified to ExPress mini shunt trabeculectomy with mitomycin C. Two years later, a patient came to the clinic because of increased values of intraocular pressure (up to 59 mmHg), slit-lamp examination showed that the ExPress implant was congested with fragments of the corneal endothelial cells. Thanks to YAG iridotomy the implant was recanalized.
</abstract>

Difficulties in Treatment of Iridocorneal Endothelial Syndrome - Case Report

<abstract xmlns="http://www.w3.org/1999/xhtml">

This article aims to present up-to-date information on ocular symptoms of pediatric multi-system inflammatory syndrome. The reviewers obtained the results based on a search of an electronic database. The pediatric multi-system inflammatory syndrome appears a few weeks after COVID-19 in children. The exact etiology remains unclear. It is diagnosed based on clinical and laboratory criteria. The most prevalent manifestation of the syndrome is non-purulent conjunctivitis (observed in around 50% of cases). The other ocular findings in the pediatric multi-system inflammatory syndrome can be; eyelid swelling, bilateral uveitis or vitreous hyperreflective dots in the posterior vitreous. The treatment of the ophthalmic symptoms is systemic and topical, targeting the enhanced inflammatory response of the organism and the presence of the given ocular findings.
</abstract>

Ocular Manifestations of Pediatric Inflammatory Multisystem Syndrome

<abstract xmlns="http://www.w3.org/1999/xhtml">

This paper aims to report clinical features, differential diagnosis and successful surgical outcome of a patient with myopic strabismus fixus, also known as Heavy Eye syndrome (HES). We present a case of a 47-year-old man who presented to the Ophthalmology Department with diplopia and poor vision. In the past, he had been diagnosed with Graves’ disease, high myopia, and secondary open-angle glaucoma. He had undergone orbital decompression and cataract surgery of both eyes. On examination, the patient had esotropia and hypotropia with limited abduction and elevation. The patient was ultimately diagnosed with HES. Yokoyama’s surgery combined with a medial rectus muscle recession in the right eye, were performed. The procedure reduced esotropia, hypotropia and improved ductions.
</abstract>

Heavy Eye Syndrome – Case Report

<abstract xmlns="http://www.w3.org/1999/xhtml">

Methionine is an essential amino critical to many cell functions including the synthesis of proteins. Supplementation of methionine in vivo is typically through L-methionine, DL-methionine, or a methionine hydroxy analog (MHA). The goal of this study was to compare the function of L-methionine, DL-methionine, and an MHA as a source of methionine to myoblasts in vitro. Avian myoblasts isolated from turkey embryos were plated in media containing varying concentrations of DL-methionine (DLM; 1.125 mg/mL or 0.56 mg/mL) or methionine hydroxy analog (MHA; 1.28 mg/mL or 0.64 mg/mL) as well as a methionine deficient negative control group and an L-methionine supplemented positive control group. The results of the proliferation assay exhibited cell division in the absence of methionine which was not significantly different than the positive control group. Results from the myoblast fusion assay revealed significantly greater myotube diameter between methionine supplemented groups compared to the methionine deficient negative control. The findings of this study show an ability for avian myoblasts to proliferate in the absence of methionine, the significance of which is discussed. Additionally, findings from the fusion assay suggest that DL-methionine and MHA are potential cost-effective substitutes for methionine supplementation during terminal differentiation of avian myoblasts.
</abstract>

The Influence of L-Methionine, DL-Methionine, and a Methionine Hydroxy Analog on Proliferation and Differentiation Potential of Avian Myoblasts

AHEAD OF PRINT

Volume 11 (2023): Issue 4 (December 2023)

Volume 11 (2023): Issue 3 (December 2023)

Volume 11 (2023): Issue 2 (September 2023)

Volume 11 (2023): Issue 1 (July 2023)

Volume 10 (2022): Issue 4 (December 2022)

Volume 10 (2022): Issue 3 (September 2022)

Volume 10 (2022): Issue 2 (June 2022)

Volume 10 (2022): Issue 1 (March 2022)

Volume 9 (2021): Issue 4 (December 2021)

Volume 9 (2021): Issue 3 (September 2021)

Volume 9 (2021): Issue 2 (June 2021)

Volume 9 (2021): Issue 1 (March 2021)

Volume 8 (2020): Issue 4 (December 2020)

Volume 8 (2020): Issue 3 (December 2020)

Volume 8 (2020): Issue 2 (June 2020)

Volume 8 (2020): Issue 1 (March 2020)

Volume 7 (2019): Issue 4 (December 2019)

Volume 7 (2019): Issue 3 (October 2019)

Volume 7 (2019): Issue 2 (September 2019)

Volume 7 (2019): Issue 1 (July 2019)

Volume 6 (2018): Issue 4 (December 2018)

Volume 6 (2018): Issue 3 (December 2018)

Volume 6 (2018): Issue 2 (September 2018)

Volume 6 (2018): Issue 1 (January 2018)

Volume 5 (2017): Issue 2 (September 2017)

Volume 5 (2017): Issue 1 (March 2017)

Volume 4 (2014): Issue 2 (December 2014)

Volume 4 (2014): Issue 1 (March 2014)

Volume 3 (2011): Issue 4 (November 2011)

Volume 3 (2011): Issue 3 (October 2011)

Volume 3 (2011): Issue 2 (June 2011)

Volume 3 (2011): Issue 1 (February 2011)

Volume 2 (2010): Issue 4 (November 2010)

Volume 2 (2010): Issue 3 (April 2010)

Volume 2 (2010): Issue 2 (February 2010)

Volume 2 (2010): Issue 1 (January 2010)

Medical Journal of Cell Biology

 Information for Polish Scientists   Zgodnie z Komunikatem Ministra Nauki i Szkolnictwa Wyższego z dnia 05 stycznia 2024 r czasopismo Medical Journal of Cell Biology uzyskało 20 punktów MNiSW.  Zachęcamy Państwa do nadsyłania artykułów zgodnych z profilem tematycznym czasopisma.     The Medical Journal of Cell Biology (MJCB) is published by Sciendo owned by De Gruyter and held by the Foundation for Cell Biology and Molecular Biology. The MJCB publishes articles in open access system in English only, four times per year, predominantly in but not limited to the field of cell biology, cell and tissue engineering, as well as translational medical studies. The journal accepts both original works, which are an innovative contribution to the field of science and critical reviews relevant to the latest literature, not older than five years. Periodically, Editor in Chief, with the permission of the Managing Editor, accepts selected Clinical Case Reports.  AIMS  Medical Journal of Cell Biology (ISSN 2544-3577) is an international, double-blind peer-reviewed, open access journal. Our predominant aim is to provide an accessible but specialized platform for researches in the field of cell biology, cell and tissue engineering, as well as translational medical studies. Manuscripts related to regenerative and reconstructive medicine are especially anticipated. Each presented methodology must be precisely described to enable reproducibility of the results. However there is no limit for the length of the manuscripts, as well as for the number of included figures and tables. MJCB provides efficient review process, followed by prompt publication of latest scientific discoveries to enrich the knowledge of researchersacross the globe.   The MJCB accepts the following types of publications: research articles, review articles, clinical case reports, letters, editorials and short communications.   SCOPE  The Medical Journal of Cell Biology accepts publications covering the following thematic areas:     Biology of human, animal and plant cells  Biology of stem cells  Biology of microbes  Biotechnology and bioengineering of cells and tissues  Nanotechnology  Reconstructive and regenerative medicine  Molecular biology  Carcinogenesis and pharmacotherapy  Macro-anatomy  Clinical Anatomy     Rejection Rate   40%   Archiving  Sciendo archives the contents of this journal in Portico - digital long-term preservation service of scholarly books, journals and collections.  Plagiarism Policy  The editorial board is participating in a growing community of Similarity Check System's users in order to ensure that the content published is original and trustworthy. Similarity Check is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process. 